杭州安道药业

Ando Pharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, specializing in the development of innovative small molecule drugs for unmet medical needs. The company's lead candidate, AND017 (enarodustat), is a HIF-PH inhibitor licensed from Japan Tobacco for the Greater China market, currently in Phase 3 trials for anemia in chronic kidney disease patients. Beyond nephrology, Ando Pharma is advancing a pipeline of oncology treatments, including AND019, a selective estrogen receptor degrader (SERD) for breast cancer. The firm is led by a team of experienced scientists and backed by prominent venture capital investors.